CAROLYN REKERDRES: Open Payments
NPI 1104020346 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$134,684 in 218 payments from 8 companies in 2025. Trend: 2023 $471 · 2024 $122,869 · 2025 $134,684
Speaker / faculty: $106,035Travel & lodging: $18,258Consulting: $6,660Food & beverage: $3,619Education: $111
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 110 | $108,794 |
| ABBVIE INC. | 37 | $24,787 |
| Teva Pharmaceuticals USA, Inc. | 17 | $282 |
| Alkermes, Inc. | 15 | $268 |
| E.R. Squibb & Sons, L.L.C. | 25 | $212 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $183 |
| Neurocrine BioSciences, Inc. | 5 | $140 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
Products named: INVEGA SUSTENNA, VRAYLAR, COBENFY, ARISTADA, CAPLYTA, INGREZZA, SPRAVATO, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
